dc.contributor.author | Cornell, Robert F. | |
dc.date.accessioned | 2020-11-05T19:20:59Z | |
dc.date.available | 2020-11-05T19:20:59Z | |
dc.date.issued | 2020-09 | |
dc.identifier.citation | Gavriatopoulou, M., Chari, A., Chen, C., Bahlis, N., Vogl, D. T., Jakubowiak, A., Dingli, D., Cornell, R. F., Hofmeister, C. C., Siegel, D., Berdeja, J. G., Reece, D., White, D., Lentzsch, S., Gasparetto, C., Huff, C. A., Jagannath, S., Baz, R., Nooka, A. K., Richter, J., … Dimopoulos, M. A. (2020). Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia, 34(9), 2430–2440. https://doi.org/10.1038/s41375-020-0756-6 | en_US |
dc.identifier.issn | 0887-6924 | |
dc.identifier.uri | http://hdl.handle.net/1803/16280 | |
dc.description | Only Vanderbilt University affiliated authors are listed on VUIR. For a full list of authors, access the version of record at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449872/ | en_US |
dc.description.abstract | Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. We reviewed 437 patients with multiple myeloma treated with selinexor and assessed the kinetics of adverse events and impact of supportive care measures. Selinexor reduced both platelets and neutrophils over the first cycle of treatment and reached a nadir between 28 and 42 days. Platelet transfusions and thrombopoietin receptor agonists were effective at treating thrombocytopenia, and granulocyte colony stimulating factors were effective at resolving neutropenia. The onset of gastrointestinal side effects (nausea, vomiting, and diarrhea) was most common during the first 1-2 weeks of treatment. Nausea could be mitigated with 5-HT3 antagonists and either neurokinin 1 receptor antagonists, olanzapine, or cannbainoids. Loperamide and bismuth subsalicylate ameliorated diarrhea. The primary constitutional side effects of fatigue and decreased appetite could be managed with methylphenidate, megestrol, cannabinoids or olanzapine, respectively. Hyponatremia was highly responsive to sodium replacement. Selinexor has well-established adverse effects that mainly occur within the first 8 weeks of treatment, are reversible, and respond to supportive care. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Leukemia | en_US |
dc.rights | Copyright © The Author(s) 2020
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. | |
dc.source.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449872/ | |
dc.title | Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1038/s41375-020-0756-6 | |